Bloomberg Portfolio Manager sees small company acquisitions June 15, 2023 - Bloomberg's " Portfolio Manager expects that the overweighting of small and mid cap companies will deliver positive results to shareholders. In particular, they expect that the divergence in the valuations of large and small/mid cap companies will close. In addition, they anticipate that we can expect to see continued consolidation in the biotechnology industry, as larger companies seek to acquire smaller companies with promising pipelines of drugs and therapies to address gaps in their own portfolios and, in many cases, impending patent expirations which threaten their future earnings. This consolidation is likely to create both opportunities and challenges for small biotechnology companies, as they navigate the changing landscape of the industry. https://www.bloomberg.com/press-releases/2023-06-15/the-biotech-growth-trust-plc-annual-financial-report "The biotechnology sector has been a critical area of innovation and growth in recent years with the rate of underlying scientific discovery and its translation into effective treatments continuing apace. With a focus on precision medicine, cell and gene therapy, digital health, and rare diseases, small biotechnology companies are at the forefront of this innovation. Additionally, advances in technology, the availability of big data and the use of artificial intelligence are enabling healthcare solutions which have the potential to revolutionise the industry." - Roger Yates Chairman